Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DCAF6 | SNV | Missense_Mutation | | c.1189N>G | p.Thr397Ala | p.T397A | Q58WW2 | protein_coding | tolerated(0.17) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCAF6 | SNV | Missense_Mutation | novel | c.2701G>A | p.Glu901Lys | p.E901K | Q58WW2 | protein_coding | tolerated(0.09) | benign(0.266) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCAF6 | SNV | Missense_Mutation | rs765173203 | c.584C>T | p.Thr195Met | p.T195M | Q58WW2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCAF6 | SNV | Missense_Mutation | | c.1258N>G | p.Gln420Glu | p.Q420E | Q58WW2 | protein_coding | tolerated_low_confidence(0.13) | benign(0.074) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
DCAF6 | SNV | Missense_Mutation | | c.190G>A | p.Glu64Lys | p.E64K | Q58WW2 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-D8-A1JH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | nolvadex | SD |
DCAF6 | SNV | Missense_Mutation | | c.2393C>T | p.Pro798Leu | p.P798L | Q58WW2 | protein_coding | tolerated(0.15) | possibly_damaging(0.478) | TCGA-E2-A1L6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
DCAF6 | insertion | Nonsense_Mutation | novel | c.2762_2763insAACTCTACTTTCTTA | p.Met921delinsIleThrLeuLeuSerTer | p.M921delinsITLLS* | Q58WW2 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DCAF6 | insertion | In_Frame_Ins | novel | c.2763_2764insCAAAAGAGTTTTTTCTTTATTGGTTTC | p.Met921_Leu922insGlnLysSerPhePhePheIleGlyPhe | p.M921_L922insQKSFFFIGF | Q58WW2 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DCAF6 | SNV | Missense_Mutation | rs745578537 | c.1244N>T | p.Ser415Phe | p.S415F | Q58WW2 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.837) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
DCAF6 | SNV | Missense_Mutation | | c.1258C>G | p.Gln420Glu | p.Q420E | Q58WW2 | protein_coding | tolerated_low_confidence(0.13) | benign(0.074) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |